<span item_type="fundamental" item_id="15ba3d8780f4275d34424ff1bdb77d9c" counter_id="ST/US/SLXNW" env="prod"></span><span item_type="announcement" item_id="581966632820413441" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -2.88.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -3.292 M.</p><p></p><h3>Financial Results for the Three Months Ended September 30, 2025</h3><h4>Research and Development (R&amp;D) Expenses</h4><ul><li>R&amp;D expenses were $2.2 million, a decrease of 31.3% from $3.2 million in the same period in 2024, primarily due to the absence of $2.4 million in non-cash share-based compensation expenses recorded in the prior-year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/exhibit_99-1.htm"></span></li></ul><h4>General and Administrative (G&amp;A) Expenses</h4><ul><li>G&amp;A expenses were $1.1 million, a decrease of 77.1% from $4.8 million in the same period in 2024, mainly attributable to the absence of $3.4 million in non-cash share-based compensation expenses recognized in the prior-year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/exhibit_99-1.htm"></span></li></ul><h4>Net Loss</h4><ul><li>Net loss was $3.3 million, or - $2.88 per share, compared to a net loss of $11.9 million, or - $274.25 per share, for the same period in 2024, representing a decrease of approximately 72.3%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/exhibit_99-1.htm"></span></li></ul><h3>Financial Results for the Nine Months Ended September 30, 2025</h3><h4>Research and Development (R&amp;D) Expenses</h4><ul><li>R&amp;D expenses were $3.8 million, a decrease of 22.4% from $4.9 million in the same period in 2024, primarily due to the absence of non-cash share-based compensation expenses recognized in the prior-year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/exhibit_99-1.htm"></span></li></ul><h4>General and Administrative (G&amp;A) Expenses</h4><ul><li>G&amp;A expenses were $3.5 million, a decrease of 38.6% from $5.7 million in the same period in 2024, mainly reflecting the absence of non-cash share-based compensation expenses and transaction costs recognized in the prior-year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/exhibit_99-1.htm"></span></li></ul><h4>Net Loss</h4><ul><li>Net loss was $7.5 million, or - $10.36 per share, compared to a net loss of $14.8 million, or - $754.85 per share, for the same period in 2024, representing a decrease of 49.3%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/exhibit_99-1.htm"></span></li></ul><h3>Balance Sheet Highlights</h3><h4>Cash and Cash Equivalents</h4><ul><li>As of September 30, 2025, cash and cash equivalents were $9.2 million, compared to $1.2 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/exhibit_99-1.htm"></span></li></ul><h4>Shareholders’ Equity</h4><ul><li>Shareholders’ equity rose to $7.0 million, a substantial improvement from a capital deficiency of - $4.0 million at year-end 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/exhibit_99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Silexion plans to initiate Phase <sup>2</sup>⁄<sub>3</sub> clinical trials for SIL204 in the first half of 2026, with regulatory submissions expected in Q4 2025 in Israel and Q1 2026 in Germany and the EU. The company aims to advance toward the clinic with precision and discipline, supported by strengthened capital structure and financial discipline.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325003756/exhibit_99-1.htm"></span></li></ul>

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 0